A clear look at the 340B program: how hospitals generate revenue from drug discounts, why it has expanded, and the growing ...

Model N, a leading end-to-end commercialization, revenue optimization, and compliance platform for life sciences companies, announced it has acquired Kalderos, a technology company that provides a ...

A judge on Tuesday rejected a challenge from major pharmaceutical companies against Washington’s new law trying to reduce ...

The past year has seen a great deal of controversy surrounding the 340B Drug Pricing Program, in which drug manufacturers make prescription drugs available to safety net healthcare providers at deeply ...

Even as they sparred on broader healthcare policy and funding topics fueling the ongoing government shutdown, senators of the Health, Education, Labor and Pensions Committee appear to agree that ...

New York lawmakers won't pass a 340B drug program protection bill this session, disappointing hospitals and health centers ...

Established under the Public Health Service Act in 1992, the 340B drug pricing program has a critical goal: improve access to medicines for low-income patients at qualifying hospitals and clinics.

B 2026 tracking litigation highlights drugmaker mandates and legal challenges reshaping hospital drug pricing and compliance risks.

The 340B program was originally designed to assist hospitals that treat under- or uninsured patients in receiving discounted pharmaceutical drugs. Now, the federal subsidy program is getting a second ...

CVS Health (NYSE:CVS) has been hit with two lawsuits from major hospital systems tied to the federal 340B drug discount program. The University of Kansas Hospital Authority and the University of ...